Evidence map›Paper›PMID 41584350›Full record

ArticleActa pharmaceutica Sinica. B2026

Attenuated

Minju Han, Eunji Kim, Minchan Jeong, Solbi Kim, Hyo-Jin Lee, Heung Jin Jeon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AttenuatedFrontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Minju HanDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Eunji KimDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Minchan JeongDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Solbi KimCancer Research Institute, Chungnam National University, Daejeon 34134, Republic of Korea.
Hyo-Jin LeeDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Heung Jin JeonCancer Research Institute, Chungnam National University, Daejeon 34134, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is characterized by an immunosuppressive state. Although PD-1/PD-L1 blockade therapy activates the immune system against tumors, it has limited long-term efficacy, prompting the development of combination therapies with targeted treatments to improve cancer treatment outcomes. Recent advancements have revitalized interest in using attenuated

Indexed as

Anti-tumor effectCombination therapyEngineering SalmonellaFlagellar type-3 secretion systemImmune checkpoint inhibitorImmunotherapyInterleukin-21Tumor microenvironment

Identifiers

PMID41584350
PMCPMC12827887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.